MarketMoversReport

Intra-Cellular Therapies Announces FDA Approval of New Dosage

看多
NASDAQ:ITCI   Intra-Cellular Therapies Inc.
ITCI: Intra-Cellular Therapies Inc.
2022-04-25 07:00:00
Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。